A. Grueters \*4, P. Heidemann<sup>2</sup>, H. Schlueter\*<sup>2</sup>, P. Stubbe<sup>2</sup>, D. l'Allemand\*4, B. Weber<sup>4</sup> and H. Helge<sup>4</sup> (introd. by H. Helge) Depts. of Pediatrics, Free University Berlin<sup>4</sup> and University of Göttingen<sup>2</sup>(F.R.G.) REDUCTION OF FINAL HEIGHT IN TALL GIRLS FOLLOWING FETDOCEN ADMINISTRATION IS NOT DOCE DEPENDANT 11 ESTROGEN ADMINISTRATION IS NOT DOSE DEPENDANT

Effects of Ethinylestradiol (EE) in girls with tall stature were assessed in a collaborative study of two centers comparing 38 girls (1), receiving 0.3 - 0.5 mg EE daily, with 44 girls on 0.1 mg EE daily (II). To minimize errors of height prediction (HP) bone ages (BA) were determined according to GREULICH and PYLE by using the mean of four determinations of both centers. Final beint (FU) we predict according to the tables of DAYLED and using the mean of four determinations of both centers. Final height (FH) was predict according to the tables of BAYLEY and PINNEAU and was measured at a chronological age (CA) of 19.8+1.2 years (y). Prior to EE administration the following findings did not differ (I vs II): CA (12.5 vs 12.4 y), BA (12.4 vs 12.4 y), length (+3,2 vs + 3.2 SDS) and HP (+3.8 vs +3.8 SDS). Evaluation of the differences between SDS of HP and SDS of FH showed no difference with respect to dose, however, an increased BA at the onset was correlated with a smaller reduction (Table I). BA 10.5-11.5y 11.75-12.75y 13 - 14 y 12.5-13.5 post menarche I 6.8/-1.22 5.45/-1.10 2.95/-0.46 5.52/-0.88 cm/-SDS(x) II 6.6/-1.12 5.31/-1.08 3.72/-0.54 5.41/-0.99 cm/-SDS(x) Cumulative dose (218+86 vs 64+20 mg), BA at the end (15+0.5 vs 15.9+0.5y) and growth after discontinuation of EE (2.7+T.8 vs 1.8+T.2 cm) did differ. 1.8+T.2 cm) did differ. Conclusion: 0.1 mg EE is as effective as 0.3 mg EE daily.

12 B.Gibson<sup>\*</sup>, S.M.Shalet, Swindell R<sup>\*</sup>, Pearson D<sup>\*</sup>. Departments of Endocrinology, Radiotherapy and Statistics, Christie Hospital & Holt Radium Inst., Manchester. England. EFFECT OF SPINAL IRRADIATION ON GROWTH

The standing height, sitting height and leg length have been measured in 79 patients (age 16-30 years), who received craniospinal (c/s) irradiation (n=37) or cranial irradiation (n=42) in childhood for a brain tumour and had completed their growth. Their measurements were compared to the established standards for sitting height and leg length in British children (age 16-18 years) (Tanner and Whitehouse, 1978). To examine the effects of spinal irradiation (DXT) on spinal growth independent of GH deficiency we analysed the leg length (LL) minus sitting height (SH) SDS and utilised the cranial group as controls. There was an overall statistically significant difference (p<0.0001) between the median c/s LL-SH SDS (1.98) and the median cranial LL-SH SDS (0.545). Within the c/s group there was a significant correlation with age at treatment (Spearman's p=0.40 : p $\lt$  0.02) but no such correlation for the cranial group. After splitting age at treatment into 3 groups (04 5, 54 10 and 10<sup>+</sup> years) there was a significant difference between the LL-SH SDS of the c/s and cranial groups for each of the age groups.

In conclusion spinal irradiation has a profound effect on spinal growth and the younger the irradiated child, the greater the subsequent skeletal disproportion. Our most conservative figures indicate that the eventual loss in height is 9cms if irradiated at one year, 7cms at five years and 5.5cms at ten years.

K.Schärer\*,D.Schönberg,K.Klinga\*,G.Gilli\*, 13 I.Gerhard \$0.Mehls \$D.E.Müller-Wiefel \$M.Trott\* Department of Pediatrics and Obstetrics, Uni-versity of Heidelberg, F.R.G.

> PUBERTAL DEVELOPMENT IN GIRLS WITH CHRONIC RENAL FAILURE (CRF)

The introduction of dialysis therapy and renal transplantation (TP) for treatment of terminal CRF in children has produced a generation of young adults with late sequelae of prc- and transpubertal uremia. Whereas growth retardation has long been recognizid as a major problem of these pts the disturbances of sex-ual maturation have been neglected. We have followed 38 girls at different stages of CRF up to age 15-26 yrs. Breast and pubic hair development and the time elapsed between stage B2 to menarche deviated from the normal range in about half of the pts. Menarche failed to enter before age 15 in 45% and was associated with advanced bone maturation (mean TW2 bone age 14.0 yrs.) Menses rarely occured on dialysis but were often re-stored after TP. Plasma E2 measured in 31 girls was decreased according to age, but usually within normal limits when related to PH stage. However, in 7 girls with advanced CRF studied repeatedly E2 did not show the expected rise. Plasma LH was increased in 35% and prolactin in 26% of cases. Response of LH to LHRH was often blunted. We conclude that in CRF the activity of the hypothalamo-pituitary-gonadal axis is frequently disturbed resulting in hypergonadotropic hypogonadism.

Z.Hochberg, R.Perlman\*, T.Bick\* 14

Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. INTRACELLULAR REGULATION OF PLACENTAL LACTOGEN (HPL) SECRETION BY CULTURED HUMAN TROPHOBLAST

To study the regulation of hPL secretion, a monolayer culture of human term trophoblast was utilized. Time course of spontane-ous secretion for 5 min to 21 hr showed a steady rate of secre-tion at 15+1,1 ng/10<sup>6</sup> cells/hr. Intracellular hPL was constant at 34+4 ng/10<sup>6</sup> cells. K<sup>+</sup> (21 mM) produced a slight but signifi-capt Thorease, from 457+13 to 584+15 ng/10<sup>6</sup> cells. GHRF (5 x 10<sup>10</sup> M) stimulated hPL secretion by 39+7%. Both dibutyryl cyclic at S474 Mg/10 certs. the second seco calmodulin inhibitor trilluoperazine eliminated the A23187 effect. It also interfered with the inhibitory effect of dbcAMP. It is concluded that: 1) the secretory mechanism of hPL is a unique process in which both dbcAMP and calcium exert inhibitory unique process in which both dbcAMP and calcium exert inhibitory action; 2) the two messengers interrelate: dbcAMP modifies cal-cium, which requires a calmodulin complex for its effect; 3) by analogy to other secretory mechanisms, the major amount of hPL is secreted by a constitutive mechanism with only small intracellu-lar storage pools; and 4) the concept of the hypothalamic-pituitary analogy applies to a small fraction of hPL secretion.

I. Henrichs\*, R. Benz\*, W.M. Teller Center of Paediatrics, Center of Gynaecology University of Ulm, Ulm, F.R.G. 15 GLUCONEOGENESIS IN HUMAN PLACENTA: EFFECTS OF INSULIN AND HYPOXIA IN VITRO

The placenta as fetal tissue is subjected to alterations of gluconeogenesis like the newborn itself. We studied tissue of term placentae incubated in amino acid solution with 14.0 mmol glucose /l under gasing with either oxigen or nitrogen. As specific inhi-bitor of gluconeogenesis 2 mM of 2,5-anhydro-D-mannitol (AM) was used, human insulin was administered at a final concentration of used, human insulin was administered at a final concentration of 180  $\mu$ U/ml. The glucose utilization (U(gluc)), L-lactate (P(lac)) and pyruvate production (P(pyr)) were calculated after tracing with (U-<sup>-</sup>C)glucose and separation by HPLC technique.- RESULTS: 1. U(gluc) was 24.8 % (+1.3 S.D.)(n=9) per g tissue in 120 min. After AM, the glucose consumption was elevated up to 33.3 % (+4.1) (p+0.01)(n=6). Insulin did not significantly influence the elevated U(gluc) in AM conditions.-2. P(lac) was lowered by AM from 18.2 % (+2.4) to 12.9 % (+2.3)(p<0.02)(n=6). Insulin abolished this effect (P(lac) up to 19.8 % (+5.7)).-3. P(pyr) remained unaltered by AM and insulin.-4. In hypoxic conditions with inhibited gluconeogenesis, elevation of U(gluc) from 38.2 % (+2.2) to 44.5 % (+6.7) was observed. Also P(lac) increased to 39.1 % (+6.6).- CONCLUSIONS: 1. Blocking of gluconeogenesis elevates the glucose utilization by one third. 2. The lactate production is reduced without gluconeogenesis, but is counteracted by insulin. 3. In without gluconeogenesis, but is counteracted by insulin. 3. In hypoxia, the gluconeogenesis continues to function in placenta.

Supported by Deutsche Forschungsgemeinschaft, He 1107/2

C.Marcus\*, P.Bolme\*, B.Karpe\* and P.Arner\* (introd. by M.Ritzén ). 16 Department of Pediatrics, Pediatric surgery and Medi-cine, Karolinska Institute, Stockholm, Sweden. THYROTROPIN AND CATECHOLAMINE INDUCED LIPOLYSIS DUR-ING THE FIRST MONTHS OF AGE.

Thyrotropin (TSH), Noradrenaline (NA), Adrenaline (A) and isoprenaline (ISNA) induced lipolysis in isolated subcutaneous adipocytes was investigated in vitro. Fat cells were obtained from 16 infants aging 2 weeks-2 months and 10 adults during inguinal hernia oper-ations. Glycerol release was measured as an index of lipolysis. NA increased lipolysis by 80% and A by 100% over the basal values in the infant group and in the adult group 300% and 200% respect-ively. With the addition of the alpha-2-blocking agent Yohimbine the differences between the doseresponse curves of the infants and adults disappeared. The effect of the beta agonist ISNA was almost identical in infants and adults (600% stimulation, ED50 10-9 M). In the infant group TSH caused a 600% stimulation of lipolysis with ED50 5x10-4 IU/ml. The TSH induced lipolysis was inhibted by preincubation of the medium with TSH antibodies but not influenced by the presence of propranolol in the medium. In the adult group TSH had no lipolytic effect below 1 unit/ml. With this concentration the mean increase was 80%. In conclusion, the lipolytic effect of catecholamines was poor during the first two months of age owing to an increased alpha-2-adrenoceptor mediated inhibition. TSH was during infancy a hormone with higher lipolytic capacity than catecholamines, the only hormones with pronounced lipolytic effect in adults. It is possible that TSH is of importance for the rise of lipolysis which is seen immediately after birth.